CombiFlow: Flow cytometry-based identification and characterization of genetically and functionally distinct AML subclones

Roos Houtsma; Shanna M Hogeling; Jan Jacob Schuringa

doi:10.1016/j.xpro.2021.100864

CombiFlow: Flow cytometry-based identification and characterization of genetically and functionally distinct AML subclones

Roos Houtsma^*, Shanna M Hogeling, Jan Jacob Schuringa^*

^*Bijbehorende auteur voor dit werk

Stem Cell Aging Leukemia and Lymphoma (SALL)

Onderzoeksoutput › Academic › peer review

39 Downloads (Pure)

Samenvatting

Many cancers, including leukemias, are dynamic oligoclonal diseases. Tools to identify and prospectively isolate genetically distinct clones for functional studies are needed. We describe our CombiFlow protocol, which is a combinatorial flow cytometry-based approach to identify and isolate such distinct clones. CombiFlow enables the visualization of clonal evolution during disease progression and the identification of potential relapse-inducing cells at minimal residual disease (MRD) time points. The protocol can be adapted to various research questions and allows functional studies on live sorted cell populations. For complete details on the use and execution of this protocol, please refer to de Boer et al. (2018).

Originele taal-2	English
Artikelnummer	100864
Aantal pagina's	17
Tijdschrift	STAR protocols
Volume	2
Nummer van het tijdschrift	4
DOI's	https://doi.org/10.1016/j.xpro.2021.100864
Status	Published - 17-dec.-2021

Toegang tot document

10.1016/j.xpro.2021.100864Licentie: CC BY

CombiFlowFinal publisher's version, 2,82 MBLicentie: CC BY

Handle.net

Permanente koppeling

Citeer dit

@article{56b115279ae64f588cf05fa50e2b92d8,

title = "CombiFlow: Flow cytometry-based identification and characterization of genetically and functionally distinct AML subclones",

abstract = "Many cancers, including leukemias, are dynamic oligoclonal diseases. Tools to identify and prospectively isolate genetically distinct clones for functional studies are needed. We describe our CombiFlow protocol, which is a combinatorial flow cytometry-based approach to identify and isolate such distinct clones. CombiFlow enables the visualization of clonal evolution during disease progression and the identification of potential relapse-inducing cells at minimal residual disease (MRD) time points. The protocol can be adapted to various research questions and allows functional studies on live sorted cell populations. For complete details on the use and execution of this protocol, please refer to de Boer et al. (2018).",

author = "Roos Houtsma and Hogeling, {Shanna M} and Schuringa, {Jan Jacob}",

note = "{\textcopyright} 2021 The Author(s).",

year = "2021",

month = dec,

day = "17",

doi = "10.1016/j.xpro.2021.100864",

language = "English",

volume = "2",

journal = "STAR protocols",

issn = "2666-1667",

number = "4",

}

TY - JOUR

T1 - CombiFlow

T2 - Flow cytometry-based identification and characterization of genetically and functionally distinct AML subclones

AU - Houtsma, Roos

AU - Hogeling, Shanna M

AU - Schuringa, Jan Jacob

PY - 2021/12/17

Y1 - 2021/12/17

N2 - Many cancers, including leukemias, are dynamic oligoclonal diseases. Tools to identify and prospectively isolate genetically distinct clones for functional studies are needed. We describe our CombiFlow protocol, which is a combinatorial flow cytometry-based approach to identify and isolate such distinct clones. CombiFlow enables the visualization of clonal evolution during disease progression and the identification of potential relapse-inducing cells at minimal residual disease (MRD) time points. The protocol can be adapted to various research questions and allows functional studies on live sorted cell populations. For complete details on the use and execution of this protocol, please refer to de Boer et al. (2018).

AB - Many cancers, including leukemias, are dynamic oligoclonal diseases. Tools to identify and prospectively isolate genetically distinct clones for functional studies are needed. We describe our CombiFlow protocol, which is a combinatorial flow cytometry-based approach to identify and isolate such distinct clones. CombiFlow enables the visualization of clonal evolution during disease progression and the identification of potential relapse-inducing cells at minimal residual disease (MRD) time points. The protocol can be adapted to various research questions and allows functional studies on live sorted cell populations. For complete details on the use and execution of this protocol, please refer to de Boer et al. (2018).

U2 - 10.1016/j.xpro.2021.100864

DO - 10.1016/j.xpro.2021.100864

M3 - Article

C2 - 34622222

SN - 2666-1667

VL - 2

JO - STAR protocols

JF - STAR protocols

IS - 4

M1 - 100864

ER -